A tighter archive for life-science signals.
Search once, then narrow by source or topic.
Prolium's $50M Series A raise; COUR Pharma touts liver drug follow-up
Prolium's $50M Series A raise; COUR Pharma touts liver drug follow-up
Theravance ends R&D, lays off 50% of workers after Phase 3 fail
Theravance ends R&D, lays off 50% of workers after Phase 3 fail
Boehringer Ingelheim tried to use a tempting, tough cancer target for liver disease. It didn’t work
Boehringer Ingelheim tried to use a tempting, tough cancer target for liver disease. It didn’t work
Hims partner Strive Pharmacy will reintroduce GLP-1 pill pulled from market
Hims partner Strive Pharmacy will reintroduce GLP-1 pill pulled from market
CMS' Chris Klomp on what it will take for AI to succeed in healthcare
CMS' Chris Klomp on what it will take for AI to succeed in healthcare
Esperion to buy Corstasis and its nasal spray for edema for $75M upfront
Esperion to buy Corstasis and its nasal spray for edema for $75M upfront
Two more members added to ACIP ahead of March meeting
Two more members added to ACIP ahead of March meeting
United Therapeutics to take pulmonary hypertension drug to FDA for approval
United Therapeutics to take pulmonary hypertension drug to FDA for approval
Aardvark's stock plummets on study pause; BioNTech heads to Phase 3 with DualityBio ADC
Aardvark's stock plummets on study pause; BioNTech heads to Phase 3 with DualityBio ADC
Roche gets third pivotal win with MS drug, but liver signal could be a problem
Roche gets third pivotal win with MS drug, but liver signal could be a problem
FDA lifts hold on second Intellia Phase 3 gene editing trial
FDA lifts hold on second Intellia Phase 3 gene editing trial
Candid to go public via reverse merger with Rallybio
Candid to go public via reverse merger with Rallybio
Bavarian Nordic CEO Paul Chaplin exits, months after failed $3B takeover
Bavarian Nordic CEO Paul Chaplin exits, months after failed $3B takeover
UniQure says FDA prefers randomized trial for Huntington's treatment
UniQure says FDA prefers randomized trial for Huntington's treatment
Novartis' Rhapsido shows promise in Phase 2 food allergy data
Novartis' Rhapsido shows promise in Phase 2 food allergy data
Merck looks to expand Welireg label following combo readouts with Keytruda, Lenvima
Merck looks to expand Welireg label following combo readouts with Keytruda, Lenvima
GLP-1 news galore; Top 100 venture investors; Doug Ingram to step down; and more
GLP-1 news galore; Top 100 venture investors; Doug Ingram to step down; and more
Ascendis wins FDA approval for achondroplasia drug, waits on EU action
Ascendis wins FDA approval for achondroplasia drug, waits on EU action
Brand directory, kept in view
A rolling strip of the companies, platforms, CROs and device makers that show up across the coverage.
Open about page